Terns Pharmaceuticals, Inc. (TERN)
Fuera de horario:
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
650 525 5535
https://www.ternspharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 66
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Erin Quirk M.D. | President & Head of Research & Development | 1.06M | N/D | 1971 |
| Dr. Mark Joseph Vignola Ph.D. | CFO & Treasurer | 974.16k | N/D | 1978 |
| Mr. Seokho Yoon Esq. | COO, General Counsel & Secretary | 921.05k | N/D | 1978 |
| Ms. Amy L. Burroughs M.B.A. | CEO & Director | N/D | N/D | 1971 |
| Dr. Jeffrey R. Jasper Ph.D. | Senior VP & Head of Research | N/D | N/D | N/D |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer | N/D | N/D | 1980 |
| Ms. Melita Sun Jung | Chief Business Officer | N/D | N/D | 1977 |
Descripción
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Terns Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 8; Compensación: 8.
